Varying prevalence of cholinesterase inhibitor (ChEI) and memantine use has been documented
across jurisdictions, likely driven by population characteristics but also by reimbursement
policies. Coverage is often not provided for persons with more severe cognitive impairment,
those who show deterioration while receiving the medications, and those on contraindicated
medications. We compared patterns and predictors of ChEI/memantine use at admission
to nursing homes in Saskatchewan and Ontario, Canada, two provinces with differing
reimbursement policies.
To read this article in full you will need to make a payment
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Alzheimer's & Dementia: The Journal of the Alzheimer's AssociationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article Info
Publication History
P4-643
Identification
Copyright
© 2019 Published by Elsevier Inc.
